The oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: The first human dose study.
Analia Azaro
No relevant relationships to disclose
José Baselga
No relevant relationships to disclose
Juan Manuel Sepúlveda
No relevant relationships to disclose
Joan Seoane
Consultant or Advisory Role - Lilly
Jordi Rodon Ahnert
Consultant or Advisory Role - Lilly
Irene Brana
No relevant relationships to disclose
Ivelina Gueorguieva
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Ann Cleverly
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Michael M. F. Lahn
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Sada Pillay
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Luis Paz-Ares
Consultant or Advisory Role - Bayer; Lilly; Pfizer; Roche
Honoraria - Bayer; Lilly; Pfizer; Roche
Matthias Holdhoff
No relevant relationships to disclose
Jaishri O'Neill Blakeley
No relevant relationships to disclose
Michael Anthony Carducci
Research Funding - Lilly